Skip to main
IGC

IGC Stock Forecast & Price Target

IGC Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

IGC Pharma is a clinical-stage pharmaceutical company with a focus on developing cannabinoid-based therapies for treating Alzheimer's disease, a growing market with significant unmet needs. The company's strong performance in patient enrollment and its reported positive interim results for its Phase 2 trial of IGC-AD1 demonstrate its potential to successfully address the symptoms of Alzheimer's disease. Despite the risks involved, the current valuation appears to be attractive and the ongoing progress and potential for growth make it a promising investment opportunity.

Bears say

IGC Pharma is a medical cannabis based company that shows potential in treating conditions such as Alzheimer's disease, period cramps, premenstrual syndrome, and chronic pain. However, with the company's minimal revenue generation and lack of Q3 guidance, it is concerning that its upcoming milestones in mid-2026 may not materialize as expected. Furthermore, the company's decision to change its fiscal year end and focus solely on Alzheimer's disease may limit its potential in exploring other medical conditions, making it a risky investment choice.

IGC has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of India Globalization Capital and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About India Globalization Capital (IGC) Forecast

Analysts have given IGC a Strong Buy based on their latest research and market trends.

According to 1 analysts, IGC has a Strong Buy consensus rating as of May 12, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $5.25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $5.25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

India Globalization Capital (IGC)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.